Years after a major trial setback, Novartis switches gears with SMA drug. This time they're trying it for Huntington's

Four years after a Phase I/II setback in spinal muscular atrophy (SMA), Novartis is hoping its drug branaplam will find more success in a new neurological indication: Huntington’s disease.